Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Candida auris has simultaneously emerged on five continents as a fungal pathogen causing nosocomial outbreaks. The challenges in the treatment of C. auris infections are the variable antifungal susceptibility profiles among clinical isolates and the development of resistance to single or multiple classes of available antifungal drugs. Here, the in vitro susceptibility to echinocandin antifungal drugs was determined and FKS1 sequencing was performed on 106 C. auris clinical isolates. Four isolates were identified to be resistant to all tested echinocandins (MIC ≥ 4 mg/liter) and harbored an S639F mutation in FKS1 hot spot region 1. All remaining isolates were FKS1 wild type (WT) and echinocandin susceptible, with micafungin being the most potent echinocandin (MIC 50 = 0.125 mg/liter). Antifungal susceptibility testing with caspofungin was challenging due to the fact that all FKS1 WT isolates exhibited an Eagle effect (also known as the paradoxical growth effect), which occurred at various intensities. To assess whether the Eagle effect resulted in pharmacodynamic resistance, 8 representative isolates were evaluated for their in vivo drug response in a murine model of invasive candidiasis. All isolates were susceptible to caspofungin at a human therapeutic dose, except for those harboring the S639F mutation. The data suggest that only isolates carrying mutations in FKS1 are echinocandin resistant and that routine in vitro testing of C. auris isolates for susceptibility to caspofungin by the broth microdilution method should be viewed cautiously or avoided.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, isochromosome (5L), a specific aneuploidy in C. albicans, results in the formation of two extra copies of the left arm of chromosome 543, and, consequently, extra copies of TAC1 and ERG11, genes that confer resistance to azoles in these strains50.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [43]
In the citing paper
“Copy number variations, including whole-chromosome aneuploidy and shorter-range amplifications, are genome changes that can increase resistance32,43–49.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [43]
In the citing paper
“Importantly, limited ECN susceptibility was reported for all 3 isolates in a previous study (36), thus confirming the robustness of our phenotyping.”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [36]
In the citing paper
“Based on CDC-suggested breakpoints for ECNs (MICs of >4 μg/mL for AFG and MFG and >2 μg/mL for CSP [37]), these isolates can be considered ECN-R, as pointed out previously (36).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [36]
In the citing paper
“The clinical features of these infections include biofilm persistence on abiotic surfaces and skin, immune evasion, and antifungal drug resistance (7–12).”
From Dual function of Candida auris mannosyltransferase, MNT5, in biofilm community protection from antifungal therapy and the host (2025) · cites this paper as [9]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
How to calculate sample size in animal studies?
Charan, J., & Kantharia, N. D. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119726 · Cited by 1,881 · cited 1×
“The sample size of this animal experiment was considered adequate on the basis of the resource equation method (49).”
MethodLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 5×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundInfluentialSelf-citationSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
First hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768
Self-citationChowdhary, A., Sharma, C., & Meis, J. F. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006290 · Cited by 750
Self-citationChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577 · cited 2×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundSelf-citationKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 12×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundResultInfluentialSelf-citationFirst Three Reported Cases of Nosocomial Fungemia Caused by Candida auris
Lee, W. G., Shin, J. H., Uh, Y., Kang, M. G., Kim, S. H., Park, K. H., & Jang, H.-C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00319-11 · Cited by 523
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454
Calvo, B., Melo, A. S. A., Perozo-Mena, A., Hernandez, M., Francisco, E. C., Hagen, F., Meis, J. F., & Colombo, A. L. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.07.008 · Cited by 448
New Clonal Strain of Candida auris, Delhi, India
Chowdhary, A., Sharma, C., Duggal, S., Agarwal, K., Prakash, A., Singh, P. K., Jain, S., Kathuria, S., Randhawa, H. S., Hagen, F., et al. (2013) · Emerging Infectious Diseases · doi:10.3201/eid1910.130393 · Cited by 418
Self-citationMultidrug-resistant endemic clonal strain of Candida auris in India
Chowdhary, A., Anil Kumar, V., Sharma, C., Prakash, A., Agarwal, K., Babu, R., Dinesh, K. R., Karim, S., Singh, S. K., Hagen, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2027-1 · Cited by 373 · cited 4×
“the AFST results of other groups (6, 27) Moreover, micafungin demonstrated the most”
BackgroundResultInfluentialSelf-citationGarcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323 · cited 1×
“albicans) cause the most pronounced resistance phenotypes (34, 37, 38).”
BackgroundSelf-citationMechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313 · cited 1×
“is amino acid substitutions in Fks subunits of glucan synthase, which decrease the sensitivity of the enzyme to the drugs (33).”
BackgroundSelf-citationKim, M., Shin, J. H., Sung, H., Lee, K., Kim, E., Ryoo, N., Lee, J., Jung, S., Park, K. H., Kee, S. J., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/597108 · Cited by 309
Vallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6544e1 · Cited by 302
Multidrug-Resistant Candida haemulonii and C. auris , Tel Aviv, Israel
Ben-Ami, R., Berman, J., Novikov, A., Bash, E., Shachor-Meyouhas, Y., Zakin, S., Maor, Y., Tarabia, J., Schechner, V., Adler, A., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.161486 · Cited by 297
Current Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274 · cited 1×
“albicans) cause the most pronounced resistance phenotypes (34, 37, 38).”
BackgroundSelf-citationArendrup, M. C., Prakash, A., Meletiadis, J., Sharma, C., & Chowdhary, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-17 · Cited by 270 · cited 3×
“auris was initially suspected to be intrinsically resistant to fluconazole, since reports dealing with Indian isolates indicated their nearly universal resistance to this drug (6, 23, 24).”
BackgroundSelf-citationCandida auris–Associated Candidemia, South Africa
Magobo, R. E., Corcoran, C., Seetharam, S., & Govender, N. P. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.131765 · Cited by 259
Garcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256 · cited 1×
“albicans) cause the most pronounced resistance phenotypes (34, 37, 38).”
BackgroundSelf-citationVallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14121 · Cited by 247
Ramage, G., VandeWalle, K., Bachmann, S. P., Wickes, B. L., & López-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3634-3636.2002 · Cited by 244
Invasive Infections with Multidrug-Resistant Yeast Candida auris , Colombia
Morales-López, S. E., Parra-Giraldo, C. M., Ceballos-Garzón, A., Martínez, H. P., Rodríguez, G. J., Álvarez-Moreno, C. A., & Rodríguez, J. Y. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2301.161497 · Cited by 243
Stevens, D. A., Espiritu, M., & Parmar, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3407-3411.2004 · Cited by 217 · cited 1×
“concentrations above the MIC, even at the lower concentration range (42).”
BackgroundEspinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216 · cited 1×
“Thus, as with many Candida species, CAS testing appears to provide an unreliable measure of resistance prevalence (44).”
BackgroundMultidrug-resistant Candida auris: ‘New kid on the block’ in hospital-associated infections?
Chowdhary, A., Voss, A., & Meis, J. F. (2016) · Journal of Hospital Infection · doi:10.1016/j.jhin.2016.08.004 · Cited by 214 · cited 2×
“The concern about resistance to azoles and amphotericin B has led to the recommendation for the use of echinocandins as a first-line therapy, pending susceptibility testing (29, 30).”
BackgroundSelf-citationSharma, C., Kumar, N., Pandey, R., Meis, J. F., & Chowdhary, A. (2016) · New Microbes and New Infections · doi:10.1016/j.nmni.2016.07.003 · Cited by 202 · cited 2×
“the AFST results of other groups (6, 27) Moreover, micafungin demonstrated the most”
BackgroundResultSelf-citationKordalewska, M., Zhao, Y., Lockhart, S. R., Chowdhary, A., Berrio, I., & Perlin, D. S. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00630-17 · Cited by 195 · cited 5×
“After vortex mixing, this DNA-containing solution was used for PCR (47).”
BackgroundInfluentialSelf-citationCandida auris Candidemia in Kuwait, 2014
Emara, M., Ahmad, S., Khan, Z., Joseph, L., Al-Obaid, I., Purohit, P., & Bafna, R. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2106.150270 · Cited by 184
Prakash, A., Sharma, C., Singh, A., Kumar Singh, P., Kumar, A., Hagen, F., Govender, N. P., Colombo, A. L., Meis, J. F., & Chowdhary, A. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.10.022 · Cited by 167
Self-citationNosocomial fungemia by Candida auris: First four reported cases in continental Europe
Ruiz Gaitán, A. C., Moret, A., López Hontangas, J. L., Molina, J. M., Aleixandre López, A. I., Cabezas, A. H., Mollar Maseres, J., Arcas, R. C., Gómez Ruiz, M. D., Chiveli, M. Á., et al. (2017) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2016.11.002 · Cited by 158
Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins
Borman, A. M., Szekely, A., & Johnson, E. M. (2017) · Medical Mycology · doi:10.1093/mmy/myw147 · Cited by 132
Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris
Berkow, E. L., & Lockhart, S. R. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.10.021 · Cited by 110
Candida auris for the Clinical Microbiology Laboratory: Not Your Grandfather's Candida Species
Lockhart, S. R., Berkow, E. L., Chow, N., & Welsh, R. M. (2017) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2017.06.003 · Cited by 93 · cited 1×
“glabrata (in the 2 to 8 mg/liter range) has increased, and fluconazole resistance is now believed to be acquired (22).”
BackgroundAraúz, A. B., Caceres, D. H., Santiago, E., Armstrong, P., Arosemena, S., Ramos, C., Espinosa‐Bode, A., Borace, J., Hayer, L., Cedeño, I., et al. (2018) · Mycoses · doi:10.1111/myc.12709 · Cited by 92
Johnson, M. E., Katiyar, S. K., & Edlind, T. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01811-10 · Cited by 91
Candidemia caused by amphotericin B and Fluconazole resistant Candida auris
Sarma, S., Kumar, N., Sharma, S., Govil, D., Ali, T., Mehta, Y., & Rattan, A. (2013) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.108746 · Cited by 91
Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection
Lepak, A. J., Zhao, M., Berkow, E. L., Lockhart, S. R., & Andes, D. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00791-17 · Cited by 89
The first cases of Candida auris candidaemia in Oman
Mohsin, J., Hagen, F., Al‐Balushi, Z. A. M., de Hoog, G. S., Chowdhary, A., Meis, J. F., & Al‐Hatmi, A. M. S. (2017) · Mycoses · doi:10.1111/myc.12647 · Cited by 83
Self-citationBrillowska‐Dąbrowska, A., Nielsen, S. S., Nielsen, H. V., & Arendrup, M. C. (2010) · Medical Mycology · doi:10.3109/13693780903531579 · Cited by 67 · cited 4×
“(S. Katiyar, personal communication), and further identified by nucleotide BLAST (https://blast.ncbi.nlm.nih.gov/ Blast.cgi) analysis, as well as real-time PCR (45).”
MethodInfluentialKatiyar, S. K., & Edlind, T. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00020-09 · Cited by 67
Shin, J. H., Kim, M.-N., Jang, S. J., Ju, M. Y., Kim, S. H., Shin, M. G., Suh, S. P., & Ryang, D. W. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06440-11 · Cited by 61
The eagle-like effect of echinocandins: what’s in a name?
Vanstraelen, K., Lagrou, K., Maertens, J., Wauters, J., Willems, L., & Spriet, I. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.841543 · Cited by 28 · cited 1×
“of antifungals, mainly in in vitro circumstances (40).”
BackgroundUse of an Animal Model of Disseminated Candidiasis in the Evaluation of Antifungal Therapy
Andes, D. (2005) · Antifungal Agents · doi:10.1385/1-59259-943-5:111 · Cited by 28 · cited 1×
“A well-established murine neutropenic disseminated candidiasis model was used for this study (48).”
MethodHospital transmittedCandida aurisinfections confirmed in the US
McCarthy, M. (2016) · BMJ · doi:10.1136/bmj.i5978 · Cited by 26
Mariné, M., Pastor, F. J., Sahand, I. H., Pontón, J., Quindós, G., & Guarro, J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00980-09 · Cited by 20 · cited 1×
“strains, despite the presence of the Eagle effect in vitro (43).”
Background
Research works printed but not linked: 2
- Public Health England. 2017. Guidance for the laboratory investigation, management and infection prevention and control for cases of Candida auris. Last updated 11 August 2017. Public Health England, London, United Kingdom.
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Candida auris: Epidemiology, biology, antifungal resistance, and virulence
Du, H., Bing, J., Hu, T., Ennis, C. L., Nobile, C. J., & Huang, G. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008921 · Cited by 609
“auris with an S639F mutation in Fks1 were caspofungin resistant, while other isolates harboring a wild-type Fks1 were susceptible to caspofungin at human therapeutic doses [74].”
BackgroundThe Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
Chow, N. A., Muñoz, J. F., Gade, L., Berkow, E., Li, X., Welsh, R. M., Forsberg, K., Lockhart, S. R., Adam, R., Alanio, A., et al. (2020) · doi:10.1101/2020.01.06.896548 · Cited by 463
Metadata
- Authors
- Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S.
- Affiliations
- Rutgers Health (US)
- Medical and Experimental Mycology Group, Corporación para Investigaciones Biológicas (CIB), Medellín, Colombia
- University of Delhi (IN)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-06
- Volume
- 62
- Issue
- 6
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5971591
- OpenAlex
- W2795884050
- Cited by
- 247
- References
- 47
- Citations by year
- 2026: 29 · 2025: 24 · 2024: 22 · 2023: 29 · 2022: 29 · 2021: 43 · 2020: 36 · 2019: 24 · 2018: 10
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (AI109025)
- Astellas Pharma US
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- Candida auris, echinocandin resistance, FKS1 mutations, caspofungin, micafungin, antifungal susceptibility testing, invasive candidiasis, mouse model, nosocomial fungal infections
- MeSH terms
- Animals, Antifungal Agents, Candida, Candidiasis, Cross Infection, Female, Glucosyltransferases, Humans, Mice, Inbred BALB C, Microbial Sensitivity Tests, Drug Resistance, Fungal, Mice, Echinocandins, Candidiasis, Invasive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.